Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice

Video content above is prompted by the following:

• Dr. O’Shaughnessy to Dr. Conlin: What is your approach to oral SERD therapy?
  • For which specific patient population would you consider using single-agent elacestrant (Bardia et al. Clin Cancer Res 2024)?
  • Do you foresee elacestrant replacing fulvestrant as the endocrine therapy backbone in combination with targeted therapies?

• Dr. Conlin to Dr. O’Shaughnessy: How do you decide which mutation to target in patients who harbor both an ESR1 and PIK3CA mutation?
  • Do you foresee a scientific rationale for a particular sequence/s of inhibitors of the PI3K pathway?